Martine Piccart

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer
    M J Piccart
    Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo 125, 1000, Brussels, Belgium
    Eur J Cancer 38:S52-4. 2002
  2. doi New developments in hormone receptor-positive disease
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institut, Brussels, Belgium
    Oncologist 15:18-28. 2010
  3. pmc Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
    Natasa Snoj
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, Brussels, Belgium
    Breast Cancer Res 11:201. 2009
  4. pmc Targeted therapies in breast cancer: are heart and vessels also being targeted?
    Carmen Criscitiello
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Breast Cancer Res 14:209. 2012
  5. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
  6. doi Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
    Otto Metzger-Filho
    Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:1954-60. 2013
  7. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
  8. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
  9. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
  10. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008

Collaborators

Detail Information

Publications95

  1. ncbi Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer
    M J Piccart
    Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo 125, 1000, Brussels, Belgium
    Eur J Cancer 38:S52-4. 2002
  2. doi New developments in hormone receptor-positive disease
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institut, Brussels, Belgium
    Oncologist 15:18-28. 2010
    ..This article addresses these important outstanding issues with respect to HR(+) disease...
  3. pmc Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
    Natasa Snoj
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, Brussels, Belgium
    Breast Cancer Res 11:201. 2009
    ....
  4. pmc Targeted therapies in breast cancer: are heart and vessels also being targeted?
    Carmen Criscitiello
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Breast Cancer Res 14:209. 2012
    ..In this review, we aim to assess the incidence of cardiac adverse events associated with targeted therapies designed to block HER2 and angiogenic pathways...
  5. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
    ....
  6. doi Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
    Otto Metzger-Filho
    Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:1954-60. 2013
    ..To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial...
  7. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
    ....
  8. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  9. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
    ..CONCLUSION: These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype...
  10. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  11. doi Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer
    M J Piccart-Gebhart
    Department of Medicine, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 18:xii2-7. 2007
    ..Close collaboration between clinicians and scientists will be essential to achieve this goal...
  12. ncbi Bringing molecular prognosis and prediction to the clinic
    Mariantonietta Colozza
    S C Oncologia Medica, Azienda Ospedaliera, Perugia, Italy
    Clin Breast Cancer 6:61-76. 2005
    ....
  13. ncbi Adjuvant chemotherapy in 2005: standards and beyond
    M J Piccart
    Medical Oncology Clinic, Jules Bordet Institute, Centre des Tumeurs de l Universite Libre de Bruxelles, Rue Heger Bordet, 1, 1000 Brussels, Belgium
    Breast 14:439-45. 2005
    ....
  14. ncbi Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  15. ncbi Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Rue Heger Bordet, 1, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Eur J Cancer 42:1715-9. 2006
    ....
  16. ncbi Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
    M J Piccart
    Jules Bordet Institute, Belgian and Luxembourg Cooperative Centers, and Pharmacia Upjohn, Brussels, Belgium
    J Clin Oncol 19:3103-10. 2001
    ....
  17. doi New developments in hormone receptor-positive disease
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institut, Brussels, Belgium
    Oncologist 16:40-50. 2011
    ..This article addresses these important outstanding issues with respect to HR(+) disease...
  18. ncbi Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
    M J Piccart
    Institut Jules Bordet, Brussels, Belgium
    Ann Oncol 12:S89-94. 2001
    ....
  19. ncbi Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
    M J Piccart
    Jules Bordet Institute, Chemotherapy Unit, Brussels, Belgium
    Ann Oncol 12:1195-203. 2001
    ....
  20. ncbi Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
    M Piccart
    Chemotherapy Unit, Internal Medicine and Oncology, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 14:1017-25. 2003
    ....
  21. ncbi The role of taxanes in the adjuvant treatment of early stage breast cancer
    Martine Piccart
    Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res Treat 79:S25-34. 2003
    ..Completion of ongoing trials and maturation of the current data will further define the role of taxanes in the adjuvant treatment of early stage breast cancer...
  22. ncbi Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
    M J Piccart
    EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium
    Int J Gynecol Cancer 13:144-8. 2003
    ....
  23. ncbi Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy
    M J Piccart
    Jules Bordet Institute, Brussels, Belgium
    Int J Gynecol Cancer 13:196-203. 2003
    ..89 (0.59-1.33) and 0.82 (0.52-1.29). These results are suggestive of a treatment benefit but do not support a change in clinical practice. Other randomized clinical trials of intraperitoneal CT are reviewed and briefly discussed...
  24. ncbi New data on chemotherapy in the adjuvant setting
    M J Piccart
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Breast 12:373-8. 2003
    ..The 3-year results of this trial strongly support concept 1; a longer follow-up and a confirmation study are desirable before recommending changes in routine patient care...
  25. doi Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
    Martine J Piccart-Gebhart
    Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    J Clin Oncol 26:1980-6. 2008
    ..This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival...
  26. ncbi Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer
    Martine Piccart
    Institut Jules Bordet, Department of Medicine, Brussels, Belgium
    Clin Breast Cancer 8:S100-13. 2008
    ....
  27. pmc Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis
    Hatem A Azim
    Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e62451. 2013
    ..SPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast cancer (BC)...
  28. pmc Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer
    Françoise Rothé
    Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 6:e20980. 2011
    ..In this study, we investigated miRNA profiling as a complementary tool to improve our understanding of breast cancer (BC) biology and to assess whether miRNA expression could predict clinical outcome of BC patients...
  29. pmc Comparison of prognostic gene expression signatures for breast cancer
    Benjamin Haibe-Kains
    Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Genomics 9:394. 2008
    ..However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms...
  30. ncbi Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial
    Andrew Bottomley
    European Organisation for Research and Treatment of Cancer, EORTC Data Center, Qualtiy of Life Unit, Brussels, Belgium
    Lancet Oncol 6:287-94. 2005
    ..We aimed to compare the effects of such an approach with those of standard chemotherapy on health-related quality of life (HRQOL)...
  31. pmc Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e66848. 2013
    ..In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its impact on treatment recommendations...
  32. doi Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis
    Michail Ignatiadis
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1996-2004. 2012
    ..To investigate the association between chemotherapy response and gene expression modules describing important biologic processes and druggable oncogenic pathways in breast cancer (BC) subtypes...
  33. doi Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment
    Christine Desmedt
    Breast Cancer Translational Research Laboratory JC Heuson, Institut Jules Bordet, 125 Bld de Waterloo, Brussels 1000, Belgium
    Clin Cancer Res 18:1004-14. 2012
    ..Based on earlier research suggesting that during breast cancer progression, striking changes occur in CD10(+) stromal cells, we aimed to better characterize this cell population and its clinical relevance...
  34. pmc Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Jérôme Toussaint
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 10:424. 2009
    ....
  35. ncbi What clinicians need to know about antioestrogen resistance in breast cancer therapy
    Amalia Milano
    Medical Oncology and Translational Research Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Eur J Cancer 42:2692-705. 2006
    ..Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed...
  36. ncbi Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
    Jan Bogaerts
    Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Nat Clin Pract Oncol 3:540-51. 2006
    ..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment...
  37. ncbi [News in the medical treatment of breast cancer]
    Martine Piccart
    Unite de Chimiotherapie, Institut Jules Bordet, 1, Rue Heger Bordet, 1000 Bruxelles, Belgique
    Bull Cancer 90:46-52. 2003
    ..For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice...
  38. doi Gene profiling assay and application: the predictive role in primary therapy
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium
    J Natl Cancer Inst Monogr 2011:124-7. 2011
    ....
  39. ncbi Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH
    Christine Desmedt
    Department of Medical Oncology, Jules Bordet Institute, Brussels
    Diagn Mol Pathol 18:22-9. 2009
    ..27 (HER2:HER2 dimers)]. These data suggest that more quantitative or functional measurements of HER2 status may facilitate the development of more personalized treatment strategies for patients with metastatic breast cancer...
  40. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
    ..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies...
  41. doi A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
    Lancet Oncol 13:e240-8. 2012
    ..We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer...
  42. ncbi The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
    ....
  43. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  44. pmc A fuzzy gene expression-based computational approach improves breast cancer prognostication
    Benjamin Haibe-Kains
    Functional Genomics and Translational Research Unit, Medical Oncology Department, Jules Bordet Institute, boulevard de Waterloo, Brussels, 1000, Belgium
    Genome Biol 11:R18. 2010
    ..In systematic evaluations, GENIUS significantly outperformed current gene signatures and clinical indices in the global population of patients...
  45. ncbi Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Fatima Cardoso
    Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
    Mol Cancer Ther 5:3042-51. 2006
    ....
  46. ncbi Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Re
    Andrew Bottomley
    Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Center, Insitut Jules Bordet, Brussels, Belgium
    J Clin Oncol 22:2576-86. 2004
    ..To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment...
  47. ncbi Use of trastuzumab for the treatment of early stage breast cancer
    Sofia Braga
    Chemotherapy Unit, Department of Medicine, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 6:1153-64. 2006
    ....
  48. ncbi Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients
    Christine Desmedt
    Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Int J Cancer 119:2539-45. 2006
    ....
  49. ncbi Breast cancer gene expression profiling: clinical trial and practice implications
    Sherene Loi
    Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Pharmacogenomics 6:49-58. 2005
    ..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care...
  50. ncbi Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
    Lissandra Dal Lago
    Translational Research Unit, Bordet Institute, Brussels, Belgium
    Mol Cancer Ther 5:2572-9. 2006
    ..This project aimed to determine the optimal scoring method for fluorescence in situ hybridization (FISH) assay...
  51. ncbi Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy
    Ivana Bozovic-Spasojevic
    BrEAST Data Center, Medical Oncology Department, Institut Jules Bordet, Boulevard de Waterloo 121, Brussels, Belgium Medical Oncology Department, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia Electronic address
    Breast 23:473-81. 2014
    ..BCL2 expression in the TU but not in the LN was predictive of increased benefit to CMF vs anthracycline-based chemotherapy. ..
  52. ncbi Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial
    Laura Biganzoli
    IDBBC Unit, EORTC IDBBC, Jules Bordet Institute, Boulevard de Waterloo 121, 7th Floor, 1000 Brussels, Belgium
    Cancer 97:40-5. 2003
    ..The potential cardiotoxicity of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies...
  53. ncbi The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Eur J Cancer 44:84-91. 2008
    ..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone...
  54. ncbi Trastuzumab for early breast cancer: current status and future directions
    Phuong Dinh
    Breast European Adjuvant Study Team, Institut Jules Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Clin Adv Hematol Oncol 5:707-17. 2007
    ..It also evaluates the current status of trastuzumab as a result of these studies and explores the possible future direction for HER2-positive breast cancers in light of recent advances in translational oncology...
  55. ncbi Biology of breast cancer during pregnancy using genomic profiling
    Hatem A Azim
    Department of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumDepartment of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Department of Forest Ecology
    Endocr Relat Cancer 21:545-54. 2014
    ..No genes were associated with DFS in a multivariate model, which could be due to low statistical power. Diagnosis during pregnancy impacts the breast cancer transcriptome including potential cancer targets. ..
  56. ncbi Progress and new standards of care in the management of HER-2 positive breast cancer
    Gaston Demonty
    Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
    Eur J Cancer 43:497-509. 2007
    ..The results of the recently reported adjuvant trials are commented, as the positive results of these trials changed the standard of care for patients with this particular type of breast cancer...
  57. ncbi Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel...
  58. pmc DNA methylation profiling reveals a predominant immune component in breast cancers
    Sarah Dedeurwaerder
    Laboratory of Cancer Epigenetics, Faculty of Medicine, Universite Libre de Bruxelles, Brussels, Belgium
    EMBO Mol Med 3:726-41. 2011
    ..The immune component uncovered here by DNA methylation profiles provides a new perspective for the importance of the microenvironment in breast cancer, holding implications for better management of breast cancer patients...
  59. pmc HER2-positive circulating tumor cells in breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    PLoS ONE 6:e15624. 2011
    ..Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging...
  60. doi [Has the time arrived for gene expression use at the bedside?]
    Véronique D'Hondt
    Service de Medecine Interne, Clinique d oncologie médicale, Institut Jules Bordet, 121, boulevard de Waterloo Bruxelles 1000, Belgique
    Bull Cancer 95:336-43. 2008
    ..Here we describe the state of the art of gene expression profiling for breast cancer, and we discuss the potential impact on breast cancer patient management considering its limits and promises...
  61. doi Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Rue Heger Bordet 1, Brussels, Belgium
    Nat Rev Clin Oncol 7:22-36. 2010
    ..Inclusion criteria for future clinical trials must be revised to account for the molecular heterogeneity of breast cancer and further optimize the role of adjuvant taxane therapy in early-stage disease...
  62. doi Aiming at the target: improved adjuvant medical therapy
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Rue Heger Bordet 1, Brussels, Belgium
    Breast 18:S25-30. 2009
    ..It is hoped that coupling prospective biomarker discovery with new drug development in earlier stages of disease will yield additional targets that can be used to guide clinical decision-making in the future...
  63. doi Facts and controversies in the use of trastuzumab in the adjuvant setting
    Phuong Dinh
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Nat Clin Pract Oncol 5:645-54. 2008
    ..This Review outlines the five adjuvant trastuzumab studies and discusses the controversies and challenges that have emerged for both the clinician and healthcare authorities worldwide as a consequence of the results from these trials...
  64. doi 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO
    Geraldine Gebhart
    Nuclear Medicine Department, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Nucl Med 54:1862-8. 2013
    ..The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients...
  65. ncbi Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study
    Gilles Freyer
    Laboratoire d Oncopharmacologie, Unite de Chimiotherapie, Service de Médecine Interne et Laboratoire d Investigation Clinique et d Oncologie Expérimentale HJ Tagnon, Institut Jules Bordet, 1000, Brussels, Belgium
    Clin Cancer Res 8:95-102. 2002
    ..For the other toxicities, which are usually cumulative, the present study has design limitations and further comparative trials are warranted...
  66. ncbi New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective
    Ahmad Awada
    Chemotherapy Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 4:53-60. 2004
    ..A clinical perspective of these agents as monotherapy or combination therapy will be presented in this paper...
  67. ncbi A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies
    Ahmad Awada
    Jules Bordet Institute, Brussels, Belgium
    Curr Med Res Opin 23:991-1003. 2007
    ..This phase I study assessed the maximum tolerated doses (MTDs), safety, pharmacokinetics, and efficacy of combined tipifarnib and docetaxel treatment in patients with advanced solid malignancies...
  68. doi New therapies for ovarian cancer: cytotoxics and molecularly targeted agents
    Phuong Dinh
    Institut Jules Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 67:103-12. 2008
    ..It will also discuss other potential signal transduction targets worthy of further evaluation in future trials...
  69. doi Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer
    Carolyn Straehle
    Breast International Group, Brussels, Belgium
    Crit Care Med 37:S22-9. 2009
    ....
  70. doi Emerging targeted agents in metastatic breast cancer
    Dimitrios Zardavas
    Institut Jules Bordet, Universite Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Nat Rev Clin Oncol 10:191-210. 2013
    ..This evolution is reflected in the molecular heterogeneity of the disease and poses severe impediments to the successful clinical development of emerging targeted agents...
  71. doi Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)
    Felipe Ades
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Belgium
    J Chemother 25:239-46. 2013
    ..We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site. ..
  72. pmc CD4⁺ follicular helper T cell infiltration predicts breast cancer survival
    Chunyan Gu-Trantien
    Molecular Immunology Unit, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Invest 123:2873-92. 2013
    ..Our identification of CD4⁺ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor...
  73. doi Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer
    Philippe L Bedard
    Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 8:S157-65. 2008
    ..Future studies with novel anti-HER2 strategies will prospectively evaluate biomarkers in an effort to further improve the outcome of women diagnosed with HER2-positive disease...
  74. pmc Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study
    Amélie Deleporte
    Medicine Department, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 14:385. 2014
    ..There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to have a major impact on patient outcome...
  75. pmc The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
    Hichame Id Boufker
    Laboratoire d Hematologie Experimentale, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 10:298. 2010
    ..It has also shown promising results in preclinical studies in various solid tumors. However, its effects on the differentiation of human osteoblasts have never been examined...
  76. doi Personalized therapy for breast cancer: a dream or a reality?
    Dimitrios Zardavas
    Institut Jules Bordet, boulevard de Waterloo, 125, 1000 Brussels, Belgium
    Future Oncol 9:1105-19. 2013
    ..Well-conducted prospective validation studies are needed if breast cancer personalized therapy is to transform from a dream into a reality. ..
  77. doi The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study
    Hatem A Azim
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Acta Oncol 51:653-61. 2012
    ..Hence, we designed a case-control study to examine tumor features and outcome in a series of BCP patients diagnosed and treated in a single institution...
  78. ncbi [Kidney cancer: from biology to clinical medicine]
    Yassine Lalami
    Institut Jules Bordet, Service de Medecine Interne, Clinique d oncologie médicale, Bruxelles, Belgique
    Rev Med Suisse 2:600-4, 606-8. 2006
  79. ncbi Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib
    Gianluca Tomasello
    Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Crit Rev Oncol Hematol 75:110-21. 2010
    ..This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases...
  80. doi Stemming resistance to HER-2 targeted therapy
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    J Mammary Gland Biol Neoplasia 14:55-66. 2009
    ..Future clinical trials should involve the integration of technologies to assess the impact of novel HER-2 targeted therapies on HER-2 positive CSCs...
  81. doi Beyond trastuzumab and lapatinib
    Dimitrios Zardavas
    From the Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, United Kingdom and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
    Am Soc Clin Oncol Educ Book 2013:2-11. 2013
    ..This paper presents the clinical data of the HER2-targeted agents under development, as well as an overview of the biologic rationale for the development of agents aimed at circumventing anti-HER2 resistance...
  82. pmc The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
    Christine Desmedt
    Institut Jules Bordet, , Brussels, Belgium
    BMC Med Genomics 2:40. 2009
    ..Validation of these results, in a larger series from BIG 1-98, is planned using the simplified GGI represented by a smaller set of genes and tested by qRT-PCR on paraffin-embedded tissues...
  83. ncbi Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer
    Philippe L Bedard
    Jules Bordet Institute, Department of Medical Oncology, Belgium
    Curr Opin Oncol 21:491-8. 2009
    ..This review will discuss the use of predictive biomarkers to tailor postmenopausal endocrine therapy...
  84. ncbi New tools for assessing breast cancer recurrence
    Phuong Dinh
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Res 141:99-118. 2008
  85. doi Clinical application of the 70-gene profile: the MINDACT trial
    Fatima Cardoso
    Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 26:729-35. 2008
    ..This article reviews the several steps in the development of the profile from its discovery to its clinical validation...
  86. ncbi Mathematics and oncology: a match for life?
    Martine J Piccart-Gebhart
    J Clin Oncol 21:1425-8. 2003
  87. doi Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    Tomasz Burzykowski
    Hasselt University, Center for Statistics, Agoralaan, Bldg D, 3590 Diepenbeek, Belgium
    J Clin Oncol 26:1987-92. 2008
    ....
  88. ncbi New stars in the sky of treatment for early breast cancer
    Martine J Piccart-Gebhart
    N Engl J Med 350:1140-2. 2004
  89. ncbi Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapy
    Martine J Piccart-Gebhart
    J Clin Oncol 23:1611-3. 2005
  90. ncbi The evolving role of aromatase inhibitors in adjuvant breast cancer therapy
    I Craig Henderson
    Carol Franc Buck Breast Care Center, University of California San Francisco Comprehensive Cancer Center, 94143, USA
    Clin Breast Cancer 6:206-15. 2005
    ..In addition, case-based discussions are included to provide direction on how to integrate recent endocrine adjuvant clinical trial findings into everyday practice...
  91. ncbi Anthracyclines and the tailoring of treatment for early breast cancer
    Martine J Piccart-Gebhart
    N Engl J Med 354:2177-9. 2006
  92. ncbi 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  93. ncbi Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
    Thomas M Suter
    Swiss Cardiovascular Center, University Hospital Bern, Inselspital, Bern, Switzerland
    J Clin Oncol 25:3859-65. 2007
    ..The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy...
  94. ncbi Individualization of therapy using Mammaprint: from development to the MINDACT Trial
    Stella Mook
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Genomics Proteomics 4:147-55. 2007
    ....